Call
Sales
866 - 285 - 7215
1-781-489-7301

Pharmaceuticals

The U.S. Market for Prescription Allergy Treatment and Management

The table of contents is not available online, please contact us for further information or look on the right hand column to see if there is a more recent version of the report

REPORT HIGHLIGHTS

  • The total, current U.S. prescription allergy treatment and management market in 2001 generated revenues of $6.45 billion. In 2006, this market is forecast to reach $9.6 billion, rising at an average annual growth rate (AAGR) of 8.3%.
  • The antihistamines and combinations segment reached $2.90 billion in 2001, some 45% of the market. Growing at an AAGR of 6.7%, this segment will reach $4 billion in 2006, but will lose ground to corticosteroids.
  • Corticosteroids are expected to rise the fastest, at an AAGR of 11.8% to $3.98 billion in 2006, representing 41.5% of the market at that time.
  • The mast cell stabilizers segment will be the second fastest growing and will rise at an AAGR of 8.9% from $340 million in 2001 to $520 million in 2006.
  • Sympathomimetics, decongestants and combinations were valued at $930 million in 2001 and will rise at an AAGR of only 3.2% to $1.09 billion in 2006.

SUMMARY FIGURE
MARKET SIZE OF U.S. PRESCRIPTION ALLERGY PRODUCTS BY PRODUCT TYPE AND REVENUES AT U.S. MANUFACTURERS’ SALES LEVELS, 1999-2006
($ Billions)
Source: BCC, Inc.